Edison Investment Research has initiated coverage of Context Therapeutics (NASDAQ:CNTX) Inc with a valuation of $134.9 million or $8.45 per share.
The shares are currently trading at $1.81.
Headquartered in Philadelphia, Context is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications.
READ: Context Therapeutics adds two new executives to strengthen its research and development team
Lead program onapristone extended-release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programs in advanced breast, endometrial and ovarian cancer, all areas with significant unmet need.
In April 2021, the company added another preclinical novel compound to the pipeline, in-licensing a bi-specific monoclonal antibody, CLDN6Xcd3.
“With multiple data readouts expected in 2022, we foresee several inflection points in the coming months,” Edison analysts said.
Contact Ritika at ritika@proactiveinvestors.com